This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Sovereign immunity in Curadev trade secret dispute splits Texas specialist court

By Melissa Ritti ( August 28, 2025, 18:19 GMT | Comment) -- On the cusp of its one-year anniversary, a divided Court of Appeals of Texas, 15th District, last week said sovereign immunity shields two cancer researchers and the University of Texas Southwestern Medical Center in trade secret litigation by India’s Curadev Pharma.Trade secret misappropriation is an intentional tort for which sovereign immunity isn't waived in the Texas Tort Claims Act, a majority panel of the Court of Appeals of Texas, 15th District, affirmed last week....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login